Lastly, although RT-qPCR confirmed increased CXCL16 expression in MDMs from psoriasis patients, there is a lack of tissue-based spatial transcriptomics or protein-level validation, and the efficacy of CXCL16 blockers in preclinical models has not been evaluated. The gene discussed is CXCL16; the disease is psoriasis.